Gossamer Bio Inc (GOSS)

03:20 AM

GOSS’s 2025 Market Dance: Up 86.05% – Time to Invest? - investchronicle.com

03:20 AM

Jul 22, 2025

Is Gossamer Bio Inc. a good long term investmentBreakthrough capital growth - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What drives Gossamer Bio Inc. stock priceTremendous portfolio expansion - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What analysts say about Gossamer Bio Inc. stockJaw-dropping returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Why Gossamer Bio Inc. stock attracts strong analyst attentionBig Return Stock Tips - Newser

Jul 22, 2025

Jul 22, 2025

What makes Gossamer Bio Inc. stock price move sharplyLow Volatility High Yield Stocks - Newser

Jul 22, 2025

Jul 19, 2025

Gossamer Bio Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - jammulinksnews.com

Jul 19, 2025

Jul 15, 2025

How Gossamer Bio Inc. stock performs during market volatilityShort Term Risk Controlled Alerts - Newser

Jul 15, 2025

Jul 15, 2025

GOSS’s Stock Market Adventure: 30.77% YTD Growth Amidst Volatility - investchronicle.com

Jul 15, 2025

Jul 14, 2025

Scotiabank Initiates Gossamer Bio at Sector Outperform With $11 Price Target - MarketScreener

Jul 14, 2025

Jul 03, 2025

Gossamer Bio (NASDAQ:GOSS) Shares Down 3.2% – Time to Sell? - Defense World

Jul 03, 2025

Jun 30, 2025

Gossamer Bio, Inc.(NasdaqGS: GOSS) added to Russell 3000 Growth Index - MarketScreener

Jun 30, 2025

Jun 30, 2025

Gossamer Bio, Inc.(NasdaqGS: GOSS) added to Russell Microcap Index - MarketScreener

Jun 30, 2025

Jun 25, 2025

Gossamer Bio Approves 2019 Incentive Award Plan - TipRanks

Jun 25, 2025

Jun 24, 2025

Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib - Insider Monkey

Jun 24, 2025

Jun 16, 2025

Gossamer Bio Announces Completion of Enrollment in Registrationa - GuruFocus

Jun 16, 2025

Jun 16, 2025

Gossamer Bio (GOSS) Wraps Up Enrollment for Phase 3 PAH Study | GOSS Stock News - GuruFocus

Jun 16, 2025

Jun 16, 2025

Gossamer Bio Announces Completion Of Enrollment In Registrational Phase 3 PROSERA Study For The Treatment Of PAH - MarketScreener

Jun 16, 2025

Jun 16, 2025

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - The Joplin Globe

Jun 16, 2025

Jun 16, 2025

Gossamer Bio's Breakthrough PAH Drug Hits Major Milestone: 390 Patients Enrolled in Phase 3 Trial - Stock Titan

Jun 16, 2025

Jun 11, 2025

Squarepoint Ops LLC Has $65,000 Stake in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World

Jun 11, 2025

Jun 11, 2025

Brokers Offer Predictions for Gossamer Bio FY2026 Earnings - Defense World

Jun 11, 2025

Jun 08, 2025

Two Sigma Investments LP Raises Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World

Jun 08, 2025

Jun 06, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rul - GuruFocus

Jun 06, 2025

Jun 06, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GOSS Stock News - GuruFocus

Jun 06, 2025

Jun 06, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule - marketscreener.com

Jun 06, 2025

Jun 06, 2025

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 06, 2025

May 26, 2025

HC Wainwright Increases Earnings Estimates for Gossamer Bio - Defense World

May 26, 2025

May 22, 2025

Cantor Fitzgerald Forecasts Gossamer Bio FY2025 Earnings - Defense World

May 22, 2025

May 20, 2025

Analyze Gossamer Bio Inc (NASDAQ: GOSS) Before Investing. - Stocksregister

May 20, 2025

May 19, 2025

Price T Rowe Associates Inc. MD Has $59,000 Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World

May 19, 2025

May 18, 2025

Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call Transcript - MSN

May 18, 2025

May 18, 2025

Wedbush Reiterates “Outperform” Rating for Gossamer Bio (NASDAQ:GOSS) - Defense World

May 18, 2025

May 18, 2025

The Goldman Sachs Group Raises Gossamer Bio (NASDAQ:GOSS) Price Target to $8.00 - Defense World

May 18, 2025

May 17, 2025

GOSS Stock Update: Analyst Reiterates Outperform Rating | GOSS S - GuruFocus

May 17, 2025

May 16, 2025

Gossamer Bio’s Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks

May 16, 2025

May 16, 2025

Gossamer Bio (GOSS): Goldman Sachs Raises Price Target to $8.00 - GuruFocus

May 16, 2025

May 16, 2025

Cantor Fitzgerald maintains Overweight on Gossamer Bio stock By Investing.com - Investing.com Nigeria

May 16, 2025